Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian graft could spare young cancer patients from early menopause

NCT ID NCT05462379

Disease control Sponsor: MARILIA ALBANEZI BERTOLAZZI Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests whether moving a piece of a woman's own ovary to the fatty tissue of her inner thigh before pelvic radiation can keep her ovaries working. The study includes 22 women aged 35 or younger with locally advanced cervical cancer. The goal is to see if the graft produces enough hormones to prevent early menopause, offering a simpler and cheaper alternative to hormone replacement therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ovarian tissue graft (autologous heterotopic fresh ovarian graft)
What this could lead to
If it works, this could offer a way for young women with cervical cancer to keep their natural hormone production after pelvic radiation, avoiding early menopause without needing hormone replacement therapy.
What could go wrong
This is an early phase 1-2 trial with only 22 participants, so results are preliminary. The graft may not produce enough hormones, and there are risks from surgery and the graft itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

22 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologic diagnosis of squamous cell carcinoma or adenocarcinoma of the cervix. * FIGO 2018 staging IB3 to IVA. * Absence of ovarian involvement. * Age ≤35 Years. * Absence of metastatic disease. * Written consent. Exclusion Criteria: * Previous treatment for cervical cancer or other malignant diseases. * Rare histology tumors. * Absence of one or both ovaries.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma premature menopause primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced cervical carcinoma Premature ovarian failure

Contacts and locations

Locations

  • Instituto do Cancer do Estado de São Paulo

    São Paulo, 01246-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.